U.S. approves first drug treatment for obstructive sleep apnoea - The Hindu
U.S. FDA approved Eli Lilly's Zepbound, a weight-loss drug, for treating moderate to severe obstructive sleep apnoea (OSA) in obese adults. Zepbound works by reducing appetite and food intake, improving OSA through weight loss. It is administered weekly with exercise and a reduced-calorie diet.
Highlighted Terms
Related News
U.S. approves first drug treatment for obstructive sleep apnoea - The Hindu
U.S. FDA approved Eli Lilly's Zepbound, a weight-loss drug, for treating moderate to severe obstructive sleep apnoea (OSA) in obese adults. Zepbound works by reducing appetite and food intake, improving OSA through weight loss. It is administered weekly with exercise and a reduced-calorie diet.